9 月 13 日，国家医疗保障局在官网发布医药购销领域商业贿赂典型案件通报，披露河北医科大学第二医院工作人员在长达 11 年时间内，累计收受商业贿赂 46 次，涉案总金额达 1.84 亿元人民币。该案暴露出部分医疗机构内部管理松散、医药购销灰色利益链条长期盘踞的突出问题。
On September 13, China's National Healthcare Security Administration (NHSA) published a notice on its official website outlining a typical case of commercial bribery in pharmaceutical and medical-device procurement. The notice revealed that staff at the Second Hospital of Hebei Medical University had taken bribes on 46 occasions over an 11-year period, totaling about 184 million yuan (roughly $25.9 million). The case exposes serious weaknesses in internal controls at some medical institutions, as well as deeply entrenched kickback networks in pharmaceutical and medical-device procurement.

国家医保局介绍，本次案件线索来自对近三年医药购销商业贿赂司法判决信息的汇总分析。早在此前上海某科贸商行涉心脏支架、球囊行贿案中，就已经曝光河北医科大学第二医院存在“每条支架收受 5000 元回扣”的犯罪事实。上海这家商行及其实际控制人，在向该院东院区心血管内科销售耗材期间，向时任副院长、心内科主任等人员支付现金回扣合计1403.33万元，双方约定支架单条回扣5000 元，单价4000元以上球囊每条回扣1000元。在该案曝光之后，仅2025年下半年，这家医院又新增9件生效的刑事司法判决，多起案件叠加后，梳理出该院工作人员受贿46次的完整事实，单次受贿最高金额达到1658万元，时间跨度最长的一笔受贿行为持续长达11年，全部贿赂累计1.84亿元。
The NHSA said the case came to light through an analysis of court judgments involving commercial bribery in pharmaceutical and medical-device procurement over the past three years. Initial evidence emerged from a separate criminal case involving a Shanghai-based trading company that supplied cardiac stents and balloon catheters. That case exposed a scheme in which staff at the Hebei hospital received kickbacks of 5,000 yuan for each stent. In connection with its sales of medical consumables to the cardiovascular department at the hospital's East Campus, the company and its controlling shareholder paid a total of 14.0333 million yuan in cash kickbacks to the then-deputy head of the hospital, the head of its cardiology department and others. The arrangement called for a 5,000-yuan kickback for each stent and 1,000 yuan for each balloon catheter costing more than 4,000 yuan. After that case came to light, nine additional criminal judgments involving individuals connected to the hospital took effect in the second half of 2025 alone. Piecing these cases together revealed the full extent of the misconduct: hospital staff had taken bribes on 46 occasions, with the largest single payment reaching 16.58 million yuan and the longest-running instance of bribery spanning 11 years. The bribes totaled 184 million yuan.
通报显示，超过30家医药、医疗器械企业长期向该院工作人员行贿，其中河北祥恩医疗器械贸易有限公司、北京金凯惠医疗器械有限责任公司、河北明视医疗器械贸易有限公司、石家庄尚道轩医疗器械商贸有限公司等 11 家企业，已经被司法机关认定构成单位行贿罪。其中河北祥恩医疗器械公司为向医院销售虚高价格的医用耗材，单独累计行贿 2064 万元，是涉案金额最高的行贿企业之一。
The notice states that more than 30 pharmaceutical and medical-device companies had bribed hospital staff over many years. Eleven of them, including Hebei Xiang'en Medical Device Trading Co., Beijing Jinkaihui Medical Device Co., Hebei Mingshi Medical Device Trading Co., and Shijiazhuang Shangdaoxuan Medical Device Trading Co., were found guilty of corporate bribery by the courts. Hebei Xiang'en Medical Device Trading Co. alone paid 20.64 million yuan in bribes to sell medical consumables at artificially inflated prices to the hospital, making it one of the companies involved with the largest amounts of bribery.
从涉案产品品类来看，贿赂资金主要围绕高值医用耗材产生，共计涉及 30 余种耗材，相关贿赂金额约 1.74 亿元，品类覆盖人工晶体、药物洗脱心脏支架、快速交换球囊扩张导管、心脏起搏器、生物可吸收医用膜等临床常用植入类耗材；除此之外还有 10 种药品卷入贿赂链条，包括注射用萘普生钠、奥拉西坦注射液、注射用兰索拉唑、盐酸纳美芬注射液等，药品相关贿赂金额合计约 1000 万元。耗材贿赂占总涉案金额九成以上，也印证高值医用耗材是医药购销腐败的高发领域。通报中暂未公开涉事医院工作人员的具体姓名与岗位信息。
By product category, the bribery centered overwhelmingly on high-value medical consumables. More than 30 types were involved, with about 174 million yuan in bribes linked to products including commonly used implantable medical devices such as intraocular lenses, drug-eluting cardiac stents, rapid-exchange balloon dilation catheters, cardiac pacemakers and bioabsorbable medical membranes. Ten types of drugs were also implicated, including naproxen sodium for injection, oxiracetam injection, lansoprazole for injection and nalmefene hydrochloride injection. Drug-related bribes totaled about 10 million yuan. Bribes involving medical consumables accounted for more than 90 percent of the total, highlighting high-value medical consumables as a major area of corruption in pharmaceutical and medical-device procurement. The notice did not disclose the names or specific positions of the hospital staff involved.
国家医保局在通报中剖析了医药购销商业贿赂背后的利益逻辑。药企通过行贿换取医生处方权、耗材使用权限，直接损害患者权益：一方面企业刻意抬高产品报价，预留回扣空间，同时通过舆论抹黑药品耗材集采，刻意制造“价格越高品质越好”的误导性说法，以此推动高价行贿产品进入医院；另一方面少数医疗机构内部形成腐败圈子，多名工作人员、多次、长期收受数十家医药企业的回扣，腐败行为持续十余年，反映出医院内部廉政教育、内控管理长期宽松软，监督机制失效。医药购销领域的灰色利益盘根错节，腐败推高医疗成本，最终会转嫁到医保基金和患者身上，阻碍集采降价惠民政策落地。
The NHSA also examined the incentives behind such bribery. Pharmaceutical and medical-device companies used bribes to influence doctors' prescribing and use of medical consumables, directly harming patients' interests. On the one hand, companies deliberately inflated their prices to create room for kickbacks, while publicly disparaging centralized procurement programs for drugs and medical consumables and promoting the misleading notion that higher-priced products are of higher quality. The aim was to get overpriced products tied to bribery schemes into hospitals. On the other hand, pockets of corruption had taken root within some medical institutions, where multiple staff members repeatedly accepted kickbacks from dozens of pharmaceutical and medical-device companies over many years. In this case, the corruption persisted for more than a decade, reflecting long-standing weaknesses in ethics training, internal controls and oversight at the hospital. These entrenched networks of illicit interests in pharmaceutical and medical-device procurement drive up healthcare costs, which are ultimately borne by public health insurance funds and patients, undermining efforts to ensure that the savings generated by centralized procurement are passed on to the public.
按照处置安排，国家医保局已经将全部案源信息移交河北省医保局。这批线索将用于两项重点工作：一是对所有涉案医药企业开展“医药价格和招采信用评价”，失信企业会面临药品耗材挂网限制、价格管控等惩戒措施；二是把案件作为重要线索，对该定点医疗机构开展飞行检查，持续深挖医保领域相关违法违规问题。
The NHSA said it had transferred all case leads to the Hebei Provincial Healthcare Security Administration. The information will be used for two key purposes. First, all companies implicated in the case will undergo a pharmaceutical pricing and procurement credit evaluation. Companies found to be in violation could face penalties, including restrictions on having their drugs and medical devices listed on the procurement platform and price controls. Second, the cases will serve as key leads for an unannounced inspection of the hospital designated by the healthcare security authorities, with further investigations into potential violations involving medical insurance.